COVID-19: FROM THE STRUCTURE AND REPLICATION CYCLE OF SARS-COV-2 TO ITS DISEASE SYMPTOMS AND TREATMENT

被引:21
作者
Zawilska, J. B. [1 ]
Lagodzinski, A. [2 ]
Berezinska, M. [3 ]
机构
[1] Med Univ Lodz, Dept Pharmacodynam, Lodz, Poland
[2] Med Univ Lodz, Dept Intervent Cardiol & Cardiac Arrhythmias, Lodz, Poland
[3] Med Univ Lodz, Dept Pharmacol & Toxicol, Lodz, Poland
来源
JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY | 2021年 / 72卷 / 04期
关键词
coronaviruses; SARS-CoV-2; COVID-19; multiorgan failure; inflammation; clinical symptoms; angiotensin converting enzyme 2; pro-inflammatory cytokines anti-COVID-19 medicines; vaccines; MULTISYSTEM INFLAMMATORY SYNDROME; RESPIRATORY-DISTRESS-SYNDROME; ACUTE KIDNEY INJURY; NEUROLOGICAL MANIFESTATIONS; STRESS-DISORDER; CORONAVIRUS; CHILDREN; MECHANISMS; INFECTION; SPECTRUM;
D O I
10.26402/jpp.2021.4.01
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
In December 2019, a small number of cases of pneumonia of unknown origin were recognized in the city of Wuhan, China. Soon, the disease, whose etiological factor was recognized as a coronavirus SARS-CoV-2, had spread across the world. The resulting CoV-associated diseases were classified by the WHO as COVID-19, and a pandemic was declared in March 2020. By 25 November 2021, there have been nearly 256.8 million of confirmed cases of COVID-19 around the world, including 5.17 million deaths. This review focuses on basal characteristics of the SARS-CoV-2 virus - its structure, replication cycle, variants and course of infection. It also briefly characterizes the currently recommended drugs and vaccines. Coronaviruses (CoVs) are a group of RNA viruses with a characteristic solar corona image observable on electron micrographs. SARS-CoV-2 possesses high affinity to human angiotensin converting enzyme 2 (ACE2) which serves as a cellular entry receptor. Its replication in human cells is accompanied by a high mutation rate. Six variants of SARS-CoV-2 have been found to be associated with essential changes of global public health significance; they are referred to as 'variants of concern' (VOC). The main route of transmission is through respiratory droplets. Although COVID-19 presents primarily as a respiratory disease, it can affect various other organs and systems that present the ACE2 protein to which the virus binds, including the heart, kidneys, intestines, liver, muscular and nervous system. COVID-19 infection can result in uncontrolled systemic hyperinflammation caused by release of a large amount of pro-inflammatory cytokines (a 'cytokine storm'), which can lead to multi-organ failure, rapid clinical deterioration and even death. Around 30% of those infected with SARS-CoV-2 remain asymptomatic, with the majority of patients demonstrating only mild or moderate symptoms; however, about 20% develop severe or critical disease. Three main groups of medications are currently recommended for therapy of COVID-19: monoclonal antibodies against the S protein of SARS-CoV-2, antiviral drugs and immunosuppressants which inhibit the cytokine storm. At present, the safest and most cost-effective way to prevent COVID-19 illness is a preventative vaccination.
引用
收藏
页码:479 / 501
页数:23
相关论文
共 50 条
  • [21] The immune response to SARS-CoV-2 and COVID-19 immunopathology -- Current perspectives
    Boechat, J. L.
    Chora, I.
    Morais, A.
    Delgado, L.
    PULMONOLOGY, 2021, 27 (05): : 423 - 437
  • [22] Progress in SARS-CoV-2, diagnostic and clinical treatment of COVID-19
    Li, Yang
    Lu, Si-Ming
    Wang, Jia-Long
    Yao, Hang-Ping
    Liang, Li Guo
    HELIYON, 2024, 10 (12)
  • [23] The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
    McLean, Gary
    Kamil, Jeremy
    Lee, Benhur
    Moore, Penny
    Schulz, Thomas F.
    Muik, Alexander
    Sahin, Ugur
    Tureci, Ozlem
    Pather, Shanti
    MBIO, 2022, 13 (02):
  • [24] Urinary SARS-CoV-2 RNA Is an Indicator for the Progression and Prognosis of COVID-19
    Zhang, Lu
    Tian, Maoqing
    Song, Yuan
    Liang, Wei
    Li, Xiaogang
    Tong, Yongqing
    Wang, Huiming
    DIAGNOSTICS, 2021, 11 (11)
  • [25] Platelets and SARS-CoV-2 During COVID-19: Immunity, Thrombosis, and Beyond
    Sciaudone, Anthony
    Corkrey, Heather
    Humphries, Fiachra
    Koupenova, Milka
    CIRCULATION RESEARCH, 2023, 132 (10) : 1272 - 1289
  • [26] Exposure risks to SARS-CoV-2 (COVID-19) in wastewater treatment plants: a review
    Mahmoudabadi, Tahereh Zarei
    Pasdar, Pirooz
    Eslami, Hadi
    SUSTAINABLE WATER RESOURCES MANAGEMENT, 2024, 10 (02)
  • [27] Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients
    Ghanbari, Reza
    Teimoori, Ali
    Sadeghi, Anahita
    Mohamadkhani, Ashraf
    Rezasoltani, Sama
    Asadi, Ebrahim
    Jouyban, Abolghasem
    Sumner, Susan C. J.
    FUTURE MICROBIOLOGY, 2020, 15 (18) : 1747 - 1758
  • [28] SARS-CoV-2 and COVID-19: A Narrative Review
    Blann, A. D.
    Heitmar, R.
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2022, 79
  • [29] Impact of SARS-CoV-2/COVID-19 on the placenta
    Menter, T.
    Tzankov, A.
    Bruder, E.
    PATHOLOGE, 2021, 42 (06): : 591 - 597
  • [30] Adaptive immunity to SARS-CoV-2 and COVID-19
    Sette, Alessandro
    Crotty, Shane
    CELL, 2021, 184 (04) : 861 - 880